Neoadjuvant endocrine therapy for resectable breast cancer: AÂ systematic review and meta-analysis

Neoadjuvant HT is a safe and feasible option, but it cannot be considered equivalent to CT. If neoadjuvant HT is performed, AIs are preferable over tamoxifen due to higher response rates.